Biogen, Inc. (BIIB)
253.27
+3.62
(+1.45%)
USD |
NASDAQ |
Oct 30, 12:57
Biogen Cash from Operations (Quarterly) : 640.80M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 640.80M |
| June 30, 2026 | 448.90M |
| March 31, 2026 | 645.50M |
| December 31, 2025 | 511.90M |
| September 30, 2025 | 1.272B |
| June 30, 2025 | 160.90M |
| March 31, 2025 | 259.30M |
| December 31, 2024 | 760.90M |
| September 30, 2024 | 935.60M |
| June 30, 2024 | 625.80M |
| March 31, 2024 | 553.20M |
| December 31, 2023 | 12.50M |
| September 30, 2023 | 592.40M |
| June 30, 2023 | 487.00M |
| March 31, 2023 | 455.30M |
| December 31, 2022 | -175.00M |
| September 30, 2022 | 661.00M |
| June 30, 2022 | 736.50M |
| March 31, 2022 | 161.80M |
| December 31, 2021 | 838.30M |
| September 30, 2021 | 805.30M |
| June 30, 2021 | 1.227B |
| March 31, 2021 | 769.00M |
| December 31, 2020 | -367.10M |
| September 30, 2020 | 1.181B |
| Date | Value |
|---|---|
| June 30, 2020 | 1.948B |
| March 31, 2020 | 1.467B |
| December 31, 2019 | 1.960B |
| September 30, 2019 | 1.695B |
| June 30, 2019 | 1.964B |
| March 31, 2019 | 1.460B |
| December 31, 2018 | 1.895B |
| September 30, 2018 | 1.736B |
| June 30, 2018 | 1.099B |
| March 31, 2018 | 1.457B |
| December 31, 2017 | 1.518B |
| September 30, 2017 | 1.628B |
| June 30, 2017 | 1.169B |
| March 31, 2017 | 235.20M |
| December 31, 2016 | 1.577B |
| September 30, 2016 | 986.60M |
| June 30, 2016 | 995.80M |
| March 31, 2016 | 1.016B |
| December 31, 2015 | 1.040B |
| September 30, 2015 | 895.45M |
| June 30, 2015 | 1.047B |
| March 31, 2015 | 733.04M |
| December 31, 2014 | 932.86M |
| September 30, 2014 | 914.03M |
| June 30, 2014 | 990.59M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 3.436B |
| Gilead Sciences, Inc. | 3.573B |
| Amgen, Inc. | 4.002B |
| Ionis Pharmaceuticals, Inc. | 565.53M |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -222.10M |
| Cash from Financing (Quarterly) | -393.80M |
| Free Cash Flow | 1.644B |
| Free Cash Flow Per Share (Quarterly) | 2.540 |
| Free Cash Flow to Equity (Quarterly) | 929.20M |
| Free Cash Flow to Firm (Quarterly) | 575.68M |
| Free Cash Flow Yield | 4.39% |